The Life Sciences team advised KBP Biosciences on its sale to Novo Nordisk of ocedurenone, a drug for uncontrolled hypertension with potential application in cardiovascular and kidney disease, for up to $1.3 billion.

Ocedurenone is an orally administered, small molecule, non-steroidal mineralocorticoid receptor antagonist that is currently being examined in the phase 3 trial CLARION-CKD in patients with uncontrolled hypertension and advanced chronic kidney disease. Uncontrolled hypertension is when a person’s blood pressure remains high despite taking two or more blood pressure-lowering treatments.

KBP Biosciences is a global, clinical-stage biotechnology company, headquartered in Singapore, focused on discovering, developing, and commercializing innovative small-molecule therapeutics for the treatment of serious cardiorenal and infectious diseases with large unmet medical needs.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark.

The Goodwin team was led by Wendy Pan, Yasin Akbari, Christopher Denn, Susan Lee, Matthew Wetzel, Catherine McCarty, Kevin Guan, Katherine Hand, Christopher Zhong, Elizabeth Mulkey, Cameron Buttermore, Ana Carolina Gentil Zattar, Longfei Fang and Heath Ingram, and included Arman Oruc, Kevin Walsh, Charlie Stewart, Timothy Holahan, Janelle Dempsey, Julie Tibbets, Daniel Karelitz, Gregg Coughlin, Boris Segalis, Karl Dragosz, Amy Josselyn, Gozde Guckaya, Emily Unger, Brian Mukherjee, Roger Cohen, Jennifer Luz, Alexandra Valenti, Danielle Fong, Madison Clausius, Tucker DeVoe.

For more details, read the press release and coverage in BioPharma Dive, Endpoints News, Fierce Biotech, Reuters and Scrip.